Halozyme Therapeutics Zukünftiges Wachstum

Future Kriterienprüfungen 5/6

Halozyme Therapeutics wird ein jährliches Gewinn- und Umsatzwachstum von 21% bzw. 15.6% prognostiziert. Der Gewinn pro Aktie wird voraussichtlich wachsen um 22.5% pro Jahr. Die Eigenkapitalrendite wird in 3 Jahren voraussichtlich 73.4% betragen.

Wichtige Informationen

21.0%

Wachstumsrate der Gewinne

22.5%

EPS-Wachstumsrate

Biotechs Gewinnwachstum	27.3%
Wachstumsrate der Einnahmen	15.6%
Zukünftige Eigenkapitalrendite	73.4%
Analystenabdeckung	Good
Zuletzt aktualisiert	04 Nov 2024

Jüngste Aktualisierungen zum künftigen Wachstum

Recent updates

Not Many Are Piling Into Halozyme Therapeutics, Inc. (NASDAQ:HALO) Just Yet

Oct 29

Halozyme Therapeutics: Behind The Pullback

Oct 22

Halozyme Therapeutics, Inc.: Significantly Undervalued Growth Based On Current Fundamentals

Aug 14

Earnings Update: Halozyme Therapeutics, Inc. (NASDAQ:HALO) Just Reported Its Yearly Results And Analysts Are Updating Their Forecasts

Feb 23

Halozyme Therapeutics: A Reasonable Value In An Overvalued Market

Jan 26

These 4 Measures Indicate That Halozyme Therapeutics (NASDAQ:HALO) Is Using Debt Safely

Jan 10

Halozyme Therapeutics, Inc.'s (NASDAQ:HALO) Intrinsic Value Is Potentially 97% Above Its Share Price

Dec 14

Is Halozyme Therapeutics (NASDAQ:HALO) A Risky Investment?

Sep 22

Halozyme Therapeutics, Inc. (NASDAQ:HALO) Shares Could Be 50% Below Their Intrinsic Value Estimate

Jul 04

We Think Halozyme Therapeutics (NASDAQ:HALO) Can Stay On Top Of Its Debt

May 09

Are Investors Undervaluing Halozyme Therapeutics, Inc. (NASDAQ:HALO) By 38%?

Mar 28

Is Halozyme Therapeutics (NASDAQ:HALO) A Risky Investment?

Jan 23

Gewinn- und Umsatzwachstumsprognosen

NasdaqGS:HALO - Zukünftige Analystenschätzungen und Finanzdaten der Vergangenheit (USD Millions)
Datum	Umsatz	Gewinne	Freier Cashflow	Bargeld aus operativen Tätigkeiten	Durchschn. Anz. Analysten
12/31/2026	1,403	689	N/A	N/A	6
12/31/2025	1,153	535	572	536	9
12/31/2024	997	440	478	487	10
9/30/2024	947	392	393	403	N/A
6/30/2024	873	337	408	420	N/A
3/31/2024	863	319	424	431	N/A
12/31/2023	829	282	373	389	N/A
9/30/2023	781	254	354	369	N/A
6/30/2023	774	234	293	306	N/A
3/31/2023	705	182	264	279	N/A
12/31/2022	660	202	235	240	N/A
9/30/2022	581	211	238	240	N/A
6/30/2022	487	366	290	292	N/A
3/31/2022	472	435	287	289	N/A
12/31/2021	443	403	298	299	N/A
9/30/2021	463	409	265	268	N/A
6/30/2021	412	229	150	152	N/A
3/31/2021	331	163	116	119	N/A
12/31/2020	268	129	53	55	N/A
9/30/2020	200	22	-24	-22	N/A
6/30/2020	180	-40	-60	-58	N/A
3/31/2020	164	-80	-89	-86	N/A
12/31/2019	196	-72	-89	-85	N/A
9/30/2019	203	-40	-55	-48	N/A
6/30/2019	182	-43	-43	-38	N/A
3/31/2019	178	-51	-36	-32	N/A
12/31/2018	152	-80	-54	-49	N/A
9/30/2018	281	46	91	93	N/A
6/30/2018	319	76	N/A	132	N/A
3/31/2018	318	68	N/A	134	N/A
12/31/2017	317	63	N/A	134	N/A
9/30/2017	166	-88	N/A	-35	N/A
6/30/2017	134	-120	N/A	-64	N/A
3/31/2017	134	-116	N/A	-60	N/A
12/31/2016	147	-103	N/A	-50	N/A
9/30/2016	160	-71	N/A	-50	N/A
6/30/2016	149	-67	N/A	-58	N/A
3/31/2016	159	-37	N/A	-36	N/A
12/31/2015	135	-32	N/A	-37	N/A
9/30/2015	113	-42	N/A	-23	N/A
6/30/2015	107	-38	N/A	-19	N/A
3/31/2015	82	-57	N/A	-44	N/A
12/31/2014	75	-68	N/A	-48	N/A
9/30/2014	57	-85	N/A	-62	N/A
6/30/2014	59	-84	N/A	-61	N/A
3/31/2014	55	-91	N/A	-56	N/A
12/31/2013	55	-83	N/A	-49	N/A

Analystenprognosen zum zukünftigen Wachstum

Einkommen vs. Sparrate: HALODas prognostizierte Gewinnwachstum (21% pro Jahr) liegt über der Sparquote (2.5%).

Ertrag vs. Markt: HALODie Erträge des Unternehmens (21% pro Jahr) werden voraussichtlich schneller wachsen als der Markt US (15.2% pro Jahr).

Hohe Wachstumserträge: HALOEs wird erwartet, dass die Erträge des Unternehmens in den nächsten 3 Jahren erheblich steigen werden.

Einnahmen vs. Markt: HALODie Einnahmen des Unternehmens (15.6% pro Jahr) werden voraussichtlich schneller wachsen als der Markt US (8.8% pro Jahr).

Hohe Wachstumseinnahmen: HALODie Einnahmen des Unternehmens (15.6% pro Jahr) werden voraussichtlich langsamer wachsen als 20% pro Jahr.

Wachstumsprognosen für den Gewinn je Aktie

Künftige Eigenkapitalrendite

Künftige Eigenkapitalrendite: HALODie Eigenkapitalrendite des Unternehmens wird in 3 Jahren voraussichtlich sehr hoch sein (73.4%).

Halozyme Therapeutics Zukünftiges Wachstum

Future Kriterienprüfungen 5/6

Wichtige Informationen

Jüngste Aktualisierungen zum künftigen Wachstum

Halozyme Therapeutics, Inc. Revises Earnings Guidance for the Year 2024

Halozyme Therapeutics, Inc. Reiterates Financial Guidance for 2024

Price target increased by 11% to US$57.11

Halozyme Therapeutics, Inc. Updates Earnings Guidance for the Full Year 2024

Price target increased by 8.3% to US$51.44

Halozyme Therapeutics, Inc. Reiterates Revenue Guidance for 2024

Recent updates

Third quarter 2024 earnings: EPS and revenues exceed analyst expectations

Halozyme Therapeutics, Inc. Revises Earnings Guidance for the Year 2024

Not Many Are Piling Into Halozyme Therapeutics, Inc. (NASDAQ:HALO) Just Yet

Halozyme Therapeutics, Inc. to Report Q3, 2024 Results on Oct 31, 2024

Halozyme Therapeutics: Behind The Pullback

President notifies of intention to sell stock

Halozyme Therapeutics, Inc. Announces FDA Approval of Roche's Subcutaneous OCREVUS ZUNOVO with ENHANZE for People with Relapsing and Primary Progressive Multiple Sclerosis

Halozyme Therapeutics, Inc. Announces FDA Approval of Roche's Tecentriq Hybreza™ With ENHANZE® for Multiple Types of Cancer

President notifies of intention to sell stock

Independent Director recently sold US$1.7m worth of stock

Halozyme Therapeutics, Inc.: Significantly Undervalued Growth Based On Current Fundamentals

Halozyme Therapeutics (NASDAQ:HALO) Has A Rock Solid Balance Sheet

Second quarter 2024 earnings: EPS and revenues exceed analyst expectations

Halozyme Therapeutics, Inc. Reiterates Financial Guidance for 2024

Senior VP & CTO notifies of intention to sell stock

Halozyme Therapeutics, Inc. to Report Q2, 2024 Results on Aug 06, 2024

Halozyme Therapeutics, Inc. (NASDAQ:HALO) Not Flying Under The Radar

Senior VP & CFO notifies of intention to sell stock

Halozyme Therapeutics, Inc. Announces Roche's OCREVUS SC with ENHANZE Receives European Commission Approval for Relapsing and Primary Progressive Multiple Sclerosis

Halozyme Therapeutics, Inc. Announces argenx Receives FDA Approval for VYVGART Hytrulo Co-Formulated with ENHANZE® for Chronic Inflammatory Demyelinating Polyneuropathy

Independent Director recently sold US$1.0m worth of stock

Independent Director notifies of intention to sell stock

Price target increased by 11% to US$57.11

Halozyme Therapeutics, Inc. Updates Earnings Guidance for the Full Year 2024

Halozyme Therapeutics: The Story Brightens

Investor sentiment improves as stock rises 19%

Senior VP & CTO exercised options and sold US$743k worth of stock

Price target increased by 8.3% to US$51.44

Halozyme Therapeutics, Inc. Reiterates Revenue Guidance for 2024

Halozyme Therapeutics, Inc. Announces the Election of Mahesh Krishnan, M.D. to its Board of Directors

Is Halozyme Therapeutics (NASDAQ:HALO) Using Too Much Debt?

Halozyme Therapeutics, Inc. to Report Q1, 2024 Results on May 07, 2024

Senior VP & Chief Technical Officer exercised options and sold US$606k worth of stock

Halozyme's Strategic Partnerships Fueling Next-Gen Therapeutics

Does Halozyme Therapeutics (NASDAQ:HALO) Deserve A Spot On Your Watchlist?

Halozyme Therapeutics, Inc., Annual General Meeting, Apr 25, 2024

Halozyme Therapeutics, Inc. (NASDAQ:HALO) Doing What It Can To Lift Shares

Senior VP & Chief Technical Officer exercised options and sold US$612k worth of stock

Senior VP & Chief Technical Officer notifies of intention to sell stock

Earnings Update: Halozyme Therapeutics, Inc. (NASDAQ:HALO) Just Reported Its Yearly Results And Analysts Are Updating Their Forecasts

Full year 2023 earnings: EPS exceeds analyst expectations

President exercised options and sold US$735k worth of stock

Halozyme Therapeutics, Inc. Provides Earnings Guidance for the Year 2024

President exercised options and sold US$601k worth of stock

Halozyme Therapeutics, Inc. to Report Q4, 2023 Results on Feb 20, 2024

Halozyme Therapeutics: A Reasonable Value In An Overvalued Market

Halozyme Announces Argenx Receives Approval in Japan for Vyvdura®? Co-Formulated with Enhanze®? for Generalized Myasthenia Gravis

Senior VP & Chief Technical Officer notifies of intention to sell stock

Halozyme Therapeutics, Inc. Provides Earnings Guidance for the Twelve Months Ended December 31, 2023

Halozyme Announces Takeda Receives FDA Approval for Hyqvia® Co-Formulated with Enhanze® as Maintenance Therapy in Adults with Chronic Inflammatory Demyelinating Polyneuropathy

Halozyme Announces Roche Receives European Commission Approval of Tecentriq®? SC with ENHANZE®? Representing the EU's First Subcutaneous PD(L)1 Cancer Immunotherapy for Multiple Cancer Types

These 4 Measures Indicate That Halozyme Therapeutics (NASDAQ:HALO) Is Using Debt Safely

Senior VP & Chief Technical Officer exercised options and sold US$544k worth of stock

Halozyme Therapeutics, Inc.'s (NASDAQ:HALO) Intrinsic Value Is Potentially 97% Above Its Share Price

Senior VP & Chief Technical Officer notifies of intention to sell stock

Third quarter 2023 earnings: EPS exceeds analyst expectations

Halozyme Therapeutics, Inc. to Report Q3, 2023 Results on Nov 06, 2023

Halozyme Therapeutics, Inc. Reports Positive Topline Results from the Phase 3 Checkmate-67T Trial Evaluating Subcutaneous (SC) Formulation of Opdivo (Nivolumab) with Enhanze

Senior VP & Chief Technical Officer notifies of intention to sell stock

Halozyme Announces Positive Clinical Data of its High-Volume Auto-Injector Demonstrating Successful Rapid Subcutaneous Drug Delivery

Is Halozyme Therapeutics (NASDAQ:HALO) A Risky Investment?

Senior VP & Chief Technical Officer notifies of intention to sell stock

Halozyme Therapeutics, Inc Announces Approval of Roche's Tecentriq® Subcutaneous (SC) with ENHANZE® in Great Britain

Independent Director recently sold US$875k worth of stock

Independent Director notifies of intention to sell stock

Second quarter 2023 earnings: EPS and revenues exceed analyst expectations

Halozyme Therapeutics, Inc. Revises Earnings Guidance for the Full Year 2023

Halozyme Therapeutics, Inc. to Report Q2, 2023 Results on Aug 08, 2023

Senior VP & Chief Technical Officer notifies of intention to sell stock